{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:27:55Z","timestamp":1786973275763,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijgc.2025.102676","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:11:37Z","timestamp":1758589897000},"page":"102676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use and outcomes of hormonal therapy for advanced-stage, low-grade serous ovarian cancer"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0847-2291","authenticated-orcid":false,"given":"Katherine","family":"Yoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9646-6697","authenticated-orcid":false,"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-1731","authenticated-orcid":false,"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-9349","authenticated-orcid":false,"given":"Jennifer S.","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Dioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2362-9525","authenticated-orcid":false,"given":"Alexandre","family":"Buckley de Meritens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn M.","family":"St Clair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarah","family":"Pua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June Y.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6390-825X","authenticated-orcid":false,"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijgc.2025.102676_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-016-2040-8","article-title":"Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria","volume":"470","author":"Hauptmann","year":"2017","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102676_bib2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/cancers14020416","article-title":"The evolution of ovarian carcinoma subclassification","volume":"14","author":"K\u00f6bel","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102676_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102676_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11912-008-0078-8","article-title":"Low-grade serous ovarian cancer: a unique disease","volume":"10","author":"Schmeler","year":"2008","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102676_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102676_bib6","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3802\/jgo.2018.29.e15","article-title":"Trends of low-grade serous ovarian carcinoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102676_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","article-title":"Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer","volume":"129","author":"Gockley","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"17","key":"10.1016\/j.ijgc.2025.102676_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034306","article-title":"Advances in precision therapy of low-grade serous ovarian cancer: a review","volume":"103","author":"Wang","year":"2024","journal-title":"Med (Baltim)"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102676_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102676_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ygyno.2021.07.027","article-title":"Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: a systematic review","volume":"163","author":"Lazurko","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102676_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102676_bib12","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN guidelines\u00ae insights: ovarian cancer","volume":"20","author":"Armstrong","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijgc.2025.102676_bib13","unstructured":"National cancer database. American College of Surgeons. Accessed November 15, 2024. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/."},{"issue":"10","key":"10.1016\/j.ijgc.2025.102676_bib14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/ijgc-2024-005677","article-title":"Secondary databases in gynecologic cancer research","volume":"34","author":"Hicks-Courant","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102676_bib15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ijgc.2025.102676_bib16","unstructured":"Commission on Cancer Accreditation. American College of Surgeons. Accessed September 1, 2024. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/commission-on-cancer\/coc-accreditation\/."},{"issue":"2 Pt 1","key":"10.1016\/j.ijgc.2025.102676_bib17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/AOG.0b013e31829ce7ec","article-title":"Survival in women with grade 1 serous ovarian carcinoma","volume":"122","author":"Nickles Fader","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102676_bib18","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","article-title":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","volume":"33","author":"Grisham","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102676_bib19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s41416-022-01897-1","article-title":"Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)","volume":"127","author":"Musacchio","year":"2022","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102676_bib20","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s11864-024-01205-4","article-title":"Targeted therapies in low-grade serous ovarian cancers","volume":"25","author":"Gonzalez","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102676_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ygyno.2020.09.049","article-title":"Endocrine therapy in the management of low-grade serous ovarian\/peritoneal carcinoma: mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors","volume":"159","author":"Gershenson","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.102676_bib22","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.102676_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ygyno.2024.08.004","article-title":"The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: a risk-set matched retrospective study","volume":"190","author":"Barakzai","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102676_bib24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis","volume":"26","author":"Wong","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ijgc.2025.102676_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005919","article-title":"GOG-3097\/ENGOT-ov81\/GTG-UK\/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator\u2019s choice of treatment in patients with recurrent low grade serous ovarian cancer","author":"Grisham","year":"2025","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25017967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25017967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:59:19Z","timestamp":1786971559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25017967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1048891X25017967"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102676","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use and outcomes of hormonal therapy for advanced-stage, low-grade serous ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102676"}}